# Flying L Partners

> Flying L Partners is a VC fund backing Health Care and Pharmaceutical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Steamboat Springs, United States
- Total investments: 7
- Last investment: Apr 2022
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/flying-l-partners
- Website: http://flyinglpartners.com/

Flying L Partners is an investment firm that aims to bring capital and know how to accelerate innovation and value creation. Its mission is to create value for investors by bringing meaningful innovation to providers and patients which improve vision and treat diseases. It adheres to the principle that if it is better medicine and better business,then value will be created. The Firm focuses on investment in healthcare industry.

## Contacts

5 contacts available for Flying L Partners. Shizune tracks 4 team members at Flying L Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/flying-l-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Pharmaceutical | 3 | 43% |
| Biopharma | 2 | 29% |
| Biotechnology | 2 | 29% |
| Medical Device | 2 | 29% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series A | 2 | 29% |
| Venture - Series Unknown | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| William J. Link | Founder, Managing Partner and Principal | 2 | — |
| Andy Corley | Partner | 0 | — |
| Jeevan Gore | Chief Operating Officer | 0 | — |
| Richard L. Lindstrom | Managing Director, Partner | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aurion Biotechnologies | Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinicallyvalidated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness. | $120M | Venture - Series Unknown | Apr 12, 2022 | https://aurionbiotech.com/ |
| TearClear | TearClear is a pharmaceutical company that specializes in providing a class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. The company was founded in 2015 and headquartered in California, United States. | $22M | Series B | Aug 11, 2020 | https://www.tearclear.com/ |
| CorneaGen | CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions.CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovativeproducts, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. | $37M | Series B | Jul 10, 2019 | http://www.corneagen.com |
| Oyster Point Pharmaceuticals | Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as anasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU). | $93M | Series B | Feb 26, 2019 | https://oysterpointrx.com/ |
| Surface Pharmaceuticals | Surface Pharmaceuticals is an owner and operator of a pharmaceutical company intended to provide ophthalmology products. The company's medicines use topical formulations with the patented Klarity delivery vehicle, designed to protect and rehabilitate the ocular surface, enabling patients with dry eye disease to recover on time and properly. |  | Series A | May 15, 2018 | http://surfacepharma.com/ |
| CorneaGen | CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions.CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovativeproducts, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. | $10M | Series A | Oct 18, 2016 | http://www.corneagen.com |

6 of 7 investments shown.

## Co-investors
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 4 deals together
- [Visionary Venture Fund](https://shizune.co/investors/profile/visionary-venture-fund) — VC Fund, 3 deals together
- Falcon Vision — VC Fund, 2 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 2 deals together
- Petrichor Healthcare Capital Management — VC Fund, 2 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Flying L Partners invest in?

Flying L Partners invests primarily in Health Care, Pharmaceutical and Biopharma startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Flying L Partners?

Public channels for Flying L Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Flying L Partners?

The team at Flying L Partners includes William J. Link (Founder, Managing Partner and Principal), Andy Corley (Partner) and Jeevan Gore (Chief Operating Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co